Antibody-modified T Cells: CARs Take the Front Seat for Hematologic Malignancies

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2014 Mar 1

PMID 24578504

Citations 319

Authors

Marcela V Maus

Stephan A Grupp

David L Porter

Carl H June

Affiliations

Soon will be listed here.

Abstract

T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been tested and reported in over 10 clinical trials. Here, we review and compare the results of the reported clinical trials and discuss the progress and key emerging factors that may play a role in effecting tumor responses. We also discuss the outlook for CAR T-cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies. Many questions remain in the field of CAR T cells directed to hematologic malignancies, but the encouraging response rates pave a wide road for future investigation.

Citing Articles

Canine Multicentric Lymphoma: Diagnostic, Treatment, and Prognostic Insights.

Rocha M, Araujo D, Carvalho F, Vale N, Pazzini J, Feliciano M Animals (Basel). 2025; 15(3).

PMID: 39943162 PMC: 11816192. DOI: 10.3390/ani15030391.

Next-generation sequencing protocol of hematopoietic stem cells (HSCs). Step-by-step overview and troubleshooting guide.

Jarczak J, Bujko K, Brzezniakiewicz-Janus K, Ratajczak M, Kucia M PLoS One. 2025; 20(1):e0313009.

PMID: 39787063 PMC: 11717189. DOI: 10.1371/journal.pone.0313009.

pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection.

Xia H, Hoang M, Schmidt E, Kiwala S, McMichael J, Skidmore Z Genome Med. 2024; 16(1):132.

PMID: 39538339 PMC: 11562694. DOI: 10.1186/s13073-024-01384-7.

Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment.

Li J, Zhang Y, Fu T, Xing G, Cai H, Li K Front Immunol. 2024; 15:1487782.

PMID: 39439803 PMC: 11493697. DOI: 10.3389/fimmu.2024.1487782.

The Biological Significance of Trogocytosis.

Agbakwuru D, Wetzel S Results Probl Cell Differ. 2024; 73:87-129.

PMID: 39242376 PMC: 11784324. DOI: 10.1007/978-3-031-62036-2_5.

References

Reshef R, Luger S, Hexner E, Loren A, Frey N, Nasta S . Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012; 367(2):135-45. PMC: 3568501. DOI: 10.1056/NEJMoa1201248. View

Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31. DOI: 10.1002/pbc.21039. View

Till B, Jensen M, Wang J, Qian X, Gopal A, Maloney D . CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012; 119(17):3940-50. PMC: 3350361. DOI: 10.1182/blood-2011-10-387969. View

Wiernik A, Foley B, Zhang B, Verneris M, Warlick E, Gleason M . Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013; 19(14):3844-55. PMC: 3715574. DOI: 10.1158/1078-0432.CCR-13-0505. View

Abate-Daga D, Hanada K, Davis J, Yang J, Rosenberg S, Morgan R . Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood. 2013; 122(8):1399-410. PMC: 3750338. DOI: 10.1182/blood-2013-04-495531. View

Singh H, Figliola M, Dawson M, Olivares S, Zhang L, Yang G . Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One. 2013; 8(5):e64138. PMC: 3669363. DOI: 10.1371/journal.pone.0064138. View

Fisher D, Chen Q, Skitzki J, Muhitch J, Zhou L, Appenheimer M . IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011; 121(10):3846-59. PMC: 3195455. DOI: 10.1172/JCI44952. View

Kochenderfer J, Dudley M, Carpenter R, Kassim S, Rose J, Telford W . Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013; 122(25):4129-39. PMC: 3862276. DOI: 10.1182/blood-2013-08-519413. View

De Oliveira S, Ryan C, Giannoni F, Hardee C, Tremcinska I, Katebian B . Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum Gene Ther. 2013; 24(10):824-39. PMC: 3787487. DOI: 10.1089/hum.2012.202. View

10.

Zakrzewski J, Suh D, Markley J, Smith O, King C, Goldberg G . Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol. 2008; 26(4):453-61. PMC: 2731996. DOI: 10.1038/nbt1395. View

11.

Micklethwaite K, Savoldo B, Hanley P, Leen A, Demmler-Harrison G, Cooper L . Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010; 115(13):2695-703. PMC: 2852368. DOI: 10.1182/blood-2009-09-242263. View

12.

Hudecek M, Schmitt T, Baskar S, Lupo-Stanghellini M, Nishida T, Yamamoto T . The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-41. PMC: 2996114. DOI: 10.1182/blood-2010-05-283309. View

13.

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

14.

Riches J, Gribben J . Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin North Am. 2013; 27(2):207-35. DOI: 10.1016/j.hoc.2013.01.003. View

15.

Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2010; 117(2):563-74. PMC: 3031480. DOI: 10.1182/blood-2010-05-284984. View

16.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

17.

Ritchie D, Neeson P, Khot A, Peinert S, Tai T, Tainton K . Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013; 21(11):2122-9. PMC: 3831035. DOI: 10.1038/mt.2013.154. View

18.

Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K . T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2012; 27(5):1107-15. DOI: 10.1038/leu.2012.341. View

19.

Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y . Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013; 21(11):2087-101. PMC: 3831041. DOI: 10.1038/mt.2013.185. View

20.

Milone M, Fish J, Carpenito C, Carroll R, Binder G, Teachey D . Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17(8):1453-64. PMC: 2805264. DOI: 10.1038/mt.2009.83. View